Medexus Pharmaceuticals's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.09.
During the past 12 months, the average EBIT per Share Growth Rate of Medexus Pharmaceuticals was -61.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -24.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Medexus Pharmaceuticals's EBIT per Share or its related term are showing as below:
MEDXF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -123.2 Med: 29.6 Max: 134.6
Current: -24
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Medexus Pharmaceuticals was 134.60% per year. The lowest was -123.20% per year. And the median was 29.60% per year.
MEDXF's 3-Year EBIT Growth Rate is ranked worse than 86.79% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs MEDXF: -24.00
Medexus Pharmaceuticals (OTCPK:MEDXF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Medexus Pharmaceuticals EBIT per Share Related Terms
Medexus Pharmaceuticals EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals (MEDXF) has a EBIT per Share of $0.09 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medexus Pharmaceuticals and its competitors. According to the industry distribution chart, Medexus Pharmaceuticals ranks #703 out of 810 companies in the Drug Manufacturers industry, placing it in the top 86.8%.
Is Medexus Pharmaceuticals' EBIT per Share too high?
Medexus Pharmaceuticals' current EBIT per Share is $0.09. The Drug Manufacturers industry median EBIT per Share is 7.50. Medexus Pharmaceuticals' value of $0.09 is 98.8% below this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #703 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medexus Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #703 out of 810 companies for EBIT per Share. This places Medexus Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 7.50. Medexus Pharmaceuticals' value of $0.09 is 98.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current EBIT per Share of $0.09 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current EBIT per Share is $0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (MEDXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.32, compared to a current price of $3.51 — trading 165.9% above its estimated fair value. The current EBIT per Share is $0.09 and 98.8% below the Drug Manufacturers industry median of 7.50. Medexus Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Medexus Pharmaceuticals (MEDXF), the current EBIT per Share is $0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of $3.51 is trading 165.9% above its estimated GF Value™ of $1.32.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEDXF:
EBIT per Share: $0.09
GF Value™: $1.32 vs. price of $3.51 (165.9% above fair value)
Industry Position: 98.8% below the Drug Manufacturers median (#703 of 810)
No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
58GF Score
Get the complete analysis for MEDXF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDXF has been successfully added to your 
